Revitalization

WORLDWIDE

Much like our bold vision for liver health, our headquarters are located in communities where revitalization is underway.

CORPORATE & U.S. HEADQUARTERSNew York

10 Hudson Yards, 37th Floor | New York, NY 10001 | T: 646-747-1000

RESEARCH & DEVELOPMENT HEADQUARTERSSan Diego

9520 Towne Centre Drive, Suite 200 | San Diego, CA 92121 | T: 858-652-6800

INTERNATIONAL HEADQUARTERSLondon

Two Pancras Square | Kings Cross, London,
N1C 4AG, UK | T:+44 203 805 7600


Austria

Fleischmarkt 1/6/12
A-1010 Vienna, Austria

T: +43 1 20 5107 3106
E: info-AT@interceptpharma.com

see more

Canada

4263 Sherwoodtowne Blvd, Suite 300
Mississauga, ON
L5B 3C3

T: +1 877-559-ICPT (4278)
E: Info-Canada@Interceptpharma.com

see more

France

Paris Madeleine
19, Boulevard Malesherbes
75008 Paris, France

T: +33 1 55 27 39 16
E: Interceptfrance@interceptpharma.com

see more

Germany

Rosenheimer Str. 52
D-81669 München, Germany

T: +49 89 4111 124 11
E: info-DE@interceptpharma.com

see more

Ireland

Ormond Building
31-36 Ormond Quay Upper, Dublin 7, Dublin, Republic of Ireland

T: +353 15274019
E: info-Ireland@interceptpharma.com

see more

Italy

Via Giosuè Carducci 24
20123 Milano, Italy

T: +39 02 66661030
E: info.italia@interceptpharma.com

see more

Luxembourg

Paris Madeleine
19, Boulevard Malesherbes
75008 Paris, France

T: +33 1 55 27 39 16
E: Interceptfrance@interceptpharma.com

see more

Portugal

Centro Empresarial Torres de Lisboa
Rua Tomás da Fonseca, Torre G, 1º Piso
1600-209 Lisboa
Portugal

T: +351 21 723 0729 or +351 21 723 0731
E: geral.pt@interceptpharma.com

see more

Spain

Paseo de la Castellana 135, 7º piso
28046 Madrid, Spain

T: +34 912 975 506

see more

Switzerland

City Center Stockerhof
Dreikönigstrasse 31A
8002 Zürich, Switzerland

T: +41 (0)44 208 3616
F: +41 (0)44 208 3500
E: info-CH@interceptpharma.com

see more

United Kingdom

Two Pancras Square
Kings Cross, London, N1C 4AG, UK

T: +44 203 805 7600
E: info-UK@interceptpharma.com

see more

Additional transparency disclosures


Since March 2018, Intercept has partnered with AOP Orphan Pharmaceuticals AG (HQ Vienna, Austria) in a number of European countries where Intercept does not have a direct affiliate presence. Although Intercept retains the Marketing Authorisation across Europe, AOP takes full commercialisation responsibility of OCALIVA in these countries.

Intercept is committed to ensuring transparency around interactions with Healthcare Professionals, Healthcare Organizations and Patient Organizations in line with legal and code obligations. The below links provide transparency disclosure information in these countries as they relate to Intercept: